A Better Deal: Medicare Discounts Surpass Estimated PBM-Negotiated Rebates

16 Aug 2024

But the amount of savings realized when the Medicare negotiated prices go into effect in 2026 remains the subject of debate.

Stakeholders are Working To Parse The Impact Of CMS negotiations. • Source: Shutterstock

The US Centers for Medicare and Medicaid Services appears to have obtained deeper discounts than rebates negotiated by pharmacy benefit managers on the 10 Medicare Part D drugs that were subject to the first price negotiation cycle.

Key Takeaways

Medicare negotiators appear to have succeeded in obtaining discounts on the 10 drugs in the program that surpass current rebates.

The agency announced the negotiated prices on 15 August. They will go into effect 1 January 2026. (Also see "

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Medicaid Changes Could Have Major Impact on Recent Coverage Improvements

07 Jul 2025

• By Tim Casey

Insurance trade groups warned that the Big Beautiful Bill destabilize Medicaid and result in the largest ever roll-back in health care coverage in the US.

Kennedy Appears Ill-Informed On Major Pharma Priorities, Creating Unique Lobbying Dynamics

04 Jul 2025

• By Sarah Karlin-Smith

The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.

US Budget Bill Eases IRA Price Controls But Coverage Losses Will Impact Pharma

04 Jul 2025

• By Cathy Kelly

The legislation expected to be signed by President Trump is a mixed bag for pharmaceutical manufacturers depending on their product mix and manufacturing situation.

How Could MFN Pricing Impact Commercial Market?

02 Jul 2025

• By Angela Maas

Industry experts forecast the impact of President Trump's Most-Favored Nation drug pricing policy on the commercial insurance industry.

US Budget Bill Eases IRA Price Controls But Coverage Losses Will Impact Pharma

04 Jul 2025

• By Cathy Kelly

The legislation expected to be signed by President Trump is a mixed bag for pharmaceutical manufacturers depending on their product mix and manufacturing situation.